New model more accurately classifies breast cancer risk
the ONA take:
Every year in America, more than a million women have breast biopsies that turn out to have benign findings. A new model, tested by a group of researchers led by Amy Degnim, M.D., a surgeon at Mayo Clinic, uses histologic features of biopsied breast tissue from benign findings along with demographic data to more accurately determine future breast cancer risk.
To test their new model, the investigators examined a cohort of approximately ten thousand women who received benign breast biopsy results from the Mayo Clinic but later developed breast cancer. The resulting age-specific incidence data was combined with a relative risk model created from both matched controls and 377 patients that later developed breast cancer.
Risk predictions from the new model were compared to the current standard, the Breast Cancer Risk Assessment Tool (BCRAT). The concordance statistic (both in the model development series and the validation series) was found to be higher in the new model than from the BCRAT.
A more accurate model for early breast cancer prediction could prove extremely useful, given that women with benign breast disease stand a higher risk of eventually developing breast cancer. This research was published in the Journal of Clinical Oncology.
Histologic features of biopsied breast tissue from benign findings along with demographic data to more accurately determine risk.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|